Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
41.35
-0.66 (-1.57%)
Jan 29, 2026, 10:30 AM EST - Market open
Twist Bioscience Revenue
In the fiscal year ending September 30, 2025, Twist Bioscience had annual revenue of $376.57M with 20.32% growth. Twist Bioscience had revenue of $99.01M in the quarter ending September 30, 2025, with 16.88% growth.
Revenue (ttm)
$376.57M
Revenue Growth
+20.32%
P/S Ratio
6.67
Revenue / Employee
$384,650
Employees
979
Market Cap
2.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 376.57M | 63.60M | 20.32% |
| Sep 30, 2024 | 312.97M | 67.87M | 27.69% |
| Sep 30, 2023 | 245.11M | 41.54M | 20.41% |
| Sep 30, 2022 | 203.57M | 71.23M | 53.83% |
| Sep 30, 2021 | 132.33M | 42.23M | 46.87% |
| Sep 30, 2020 | 90.10M | 35.72M | 65.67% |
| Sep 30, 2019 | 54.39M | - | - |
| Jun 30, 2019 | 54.39M | 28.96M | 113.89% |
| Sep 30, 2018 | 25.43M | - | - |
| Jun 30, 2018 | 25.43M | 14.66M | 136.16% |
| Sep 30, 2017 | 10.77M | 8.50M | 374.53% |
| Sep 30, 2016 | 2.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 1.97B |
| Sotera Health Company | 1.15B |
| Neogen | 880.32M |
| NeoGenomics | 709.16M |
| OPKO Health | 642.07M |
| Veracyte | 495.14M |
| GeneDx Holdings | 402.19M |
| CareDx | 358.00M |
TWST News
- 16 days ago - Twist Bioscience Corporation (TWST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue - Business Wire
- 6 weeks ago - Twist Bioscience to Present at J.P. Morgan 2026 Healthcare Conference - Business Wire
- 6 weeks ago - Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 2 months ago - Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research - Business Wire
- 2 months ago - Twist Bioscience Is Bent, Not Broken: Near-Term Strain, Long-Term Strength - Seeking Alpha
- 2 months ago - Can Twist Bioscience Drop More? - Forbes
- 2 months ago - Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript - Seeking Alpha